TMS Database Registry Consortium Research in Japan - TReC-J

Mimura Masaru0 个研究点目标入组 4,800 人开始时间: 2021年8月5日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1) Currently receiving or planning to receive TMS therapy, regardless of whether it is covered by insurance, private practice, or clinical research.
•2) Age 18 years and older at the time of obtaining consent.
•3) Written consent for participation in the study has been obtained from the research subject or a substitute.
•Consent by a substitute will only be required if the research participant is a minor or has cognitive impairment.
•However, in the case of patients who have received TMS treatment in the past and cannot be contacted for explanation and consent, the data can be used after giving them the opportunity to refuse secondary use of the data by publishing an opt-out document on the website of the study period (Appendix 4: Opt-out document). In this case, age at the time of obtaining consent in selection criterion 2) should be replaced with age at the time of (starting) TMS treatment.

•1) Those whom the investigators consider unable to complete the planned treatment at any point prior to the start of TMS therapy.
•2) Those whom the investigators judge that TMS therapy is not effective for the study subjects.
•3) Patients with any of the following complications:
•- Organic brain disease (e.g., intracranial organic lesions of moderate severity or more, neurodegenerative disease)
•- Substance-related disorders in the 6 months prior to the start of TMS treatment
•- Serious or unstable physical illness.
•4) Patients with a history of any of the following:
•Seizures or epilepsy (except for febrile convulsions in childhood)
•5) Others who have been judged by the principal investigators or co-investigators to be inappropriate as subjects in the data collection of this research.

发起方

Mimura Masaru